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Acute kidney injury is a common complication of acute
myocardial infarction and is generally associated with
adverse outcomes. We studied the incidence and clinical
significance of transient versus persistent acute kidney injury
in 1957 patients who survived an ST-elevation acute
myocardial infarction. We divided the patients into 5 groups
based on changes in serum creatinine level during
hospitalization. Mild acute kidney injury (creatinine
0.3–0.49mg/dl above baseline) occurred in 156 patients and
was transient (resolved during their hospital stay) in 61.
Moderate/severe acute kidney injury (creatinine more than or
0.5mg/dl above baseline) was found in 138 patients and was
transient in 60. Compared to patients without acute kidney
injury, the adjusted hazard ratio for mortality was 1.2 in
patients with mild, transient acute kidney injury and 1.8 in
patients with mild, persistent injury where the creatinine
remained elevated. Patients with persistent moderate/severe
acute kidney injury had the highest mortality (hazard ratio
2.4), whereas patients with transient moderate/severe injury
had an intermediate risk (hazard ratio of 1.7). A similar
relationship was present between acute kidney injury and
admissions for heart failure. Our study shows that dynamic
changes in renal function during acute myocardial infarction
are strongly related to long-term mortality and heart failure.
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Acute kidney injury (AKI) is a common complication of
acute myocardial infarction (AMI) and other critical illness.
Recently, there has been growing interest in the association
between worsening kidney function during hospitalization
and the risk of short- and long-term mortality in various
cardiac conditions.1–5 In patients with AMI, AKI is associated
with poor outcome and independently predicts increased
in-hospital and long-term mortality up to 10 years of
follow-up.3,4,6
However, several important questions remain unanswered
regarding the prognostic implications of AKI. In previous
investigations, AKI was defined and analyzed as a dichot-
omous event that occurs during hospitalization.1–4,7,8 In
reality, there are dynamic changes in renal function and AKI
during the acute phase of AMI can be a reversible, short-lived
phenomenon that will resolve by discharge. In such cases,
AKI is likely to be associated with a lower risk during long-
term follow-up. By contrast, AKI after AMI may be partly or
completely irreversible or even lead to progressive deteriora-
tion of renal function and development of chronic kidney
disease, which has a profound impact on cardiovascular
outcomes in patients with acute coronary syndromes2,9–11 as
well as in the general population.12–14
The clinical implications of transient vs persistent AKI in
the setting of AMI are unknown. Therefore, we sought to
define the incidence and prognostic implications of transient
vs persistent AKI in patients with acute ST-elevation
myocardial infarction (STEMI).
RESULTS
Between January 2000 and August 2007, a total of 2279
patients presenting with acute myocardial infarction were
enrolled. A total of 65 (2.5%) patients were excluded because
of missing repeated creatinine measurements during hospi-
talization. In addition, 257 patients were excluded because of
in-hospital death. These patients had higher serum creatinine
level at admission compared with patients who survived the
index event (1.3±0.8 vs 1.0±0.4 mg per 100 ml; Po0.0001).
Repeated serum creatinine measurements were available in
201 patients who died during hospital course, with mild AKI
and moderate/severe AKI occurring in 10.4 and 36.3% of
or ig ina l a r t i c l e http://www.kidney-international.org
& 2009 International Society of Nephrology
Received 25 January 2009; revised 25 May 2009; accepted 23 June 2009;
published online 5 August 2009
Correspondence: Doron Aronson, Department of Cardiology, Rambam
Medical Center, Bat Galim, PO Box 9602, Haifa 31096, Israel.
E-mail: daronson@tx.technion.ac.il
900 Kidney International (2009) 76, 900–906
patients, respectively. Of these, 10 (3.9%) patients received
renal replacement therapy.
The study population consisted of the remaining 1957
patients who survived the index event and were discharged
from hospital in stable condition. During hospital course,
mild and moderate/severe AKI occurred in 156 (8.0%) and
138 (7.1%) patients, respectively. Mild AKI was transient in
61 (39.1%) patients, and moderate/severe AKI was transient
in 60 (43.5%) patients. Renal replacement therapy was used
during hospitalization in 14 (0.7%) patients.
Demographic and clinical characteristics of the five study
groups are shown in Table 1. AKI during hospital course was
associated with older age and the history of hypertension and
diabetes. Patients with AKI had higher creatinine and lower
estimated glomerular filtration rate (eGFR) levels at baseline.
They presented with higher Killip class and were more likely
to have an anterior infarction. They were less likely to receive
primary angioplasty and thrombolytic therapy.
Patients with transient and mild AKI were similar in their
baseline creatinine and peak creatinine level and differed
only in their pre-discharge creatinine levels (Po0.0001;
Figure 1a). Similarly, patients with moderate/severe AKI
differed only in their pre-discharge creatinine levels
(Po0.0001; Figure 1b).
Multivariable logistic regression model identified age
(odds ratio (OR): 1.3, 95% CI: 1.2–1.5 per 10 years increase),
baseline eGFR (OR: 1.6, 95% CI: 1.2–2.3 for eGFR 60–89 ml/
min compared with eGFR X90 ml/min and OR: 7.3, 95%
CI: 3.2–16.5 for eGFR o59 ml/min compared with eGFR
X90 ml/min), history of hypertension (OR 1.7, 95% CI
1.3–2.3), anterior infarction (OR: 1.6, 95% CI: 1.2–2.2), Killip
class 4I at admission (OR: 2.4, 95% CI: 1.7–3.3), not
receiving reperfusion therapy (OR: 1.5, 95% CI: 1.1–2.0), and
left ventricular ejection fraction o45% (OR: 1.6, 95% CI:
1.2–2.1), as independent predictors of any AKI during
hospital course.
AKI and long-term mortality
The median duration of follow-up after hospital discharge
was 36 months (range, 9–60). During the follow-up
period, 227 (11.6%) patients died. The Kaplan–Meier survival
curves for the AKI groups separated early, yielding a
statistically significant difference in mortality at 30-days after
hospital discharge (log-rank Po0.0001). The separation of
the curves continued throughout the follow up period, with
increased probability of death during follow up with
increasing degrees of AKI (Figure 2). However, in each of
the AKI subgroups, the long-term mortality of patients
with transient AKI was better than that of patients with
persistent AKI.
The results of a multivariable Cox proportional hazards
model adjusting for other potential clinical predictors of
mortality are shown in Table 2. The univariable Cox
proportional hazards model indicated a graded increase in
post-discharge mortality with increasing severity of AKI. The
effect of AKI on mortality observed in crude analyses was
Table 1 | Baseline clinical characteristics according to acute kidney injury categories
Mild AKI Moderate/severe AKI
Characteristics No AKI (n=1663) Transient (n=61) Persistent (n=95) Transient (n=60) Persistent (n=78) P-value
Age (years) 59±12 64±12 65±13 70±12 69±13 o0.0001
Male gender 1335 (80) 47 (77) 71 (75) 44 (73) 57 (73) 0.24
Hypertension 681 (41) 30 (49) 65 (68) 39 (65) 50 (64) o0.0001
Smoking 875 (53) 28 (46) 33 (35) 21 (35) 30 (39) o0.0001
Diabetes 414 (25) 22 (36) 31 (33) 23 (38) 23 (29) 0.02
Previous infarction 333 (20) 13 (21) 21 (22) 18 (30) 24 (31) 0.08
Anterior infarction 660 (40) 31 (51) 49 (52) 41 (68) 41 (53) o0.0001
Killip class II–IV 249 (15) 20 (33) 28 (30) 36 (60) 35 (45) o0.0001
SBP on admission (mmHg) 132±25 134±26 136±31 134±26 132±25 0.30
Heart rate on admission (beats/min) 77±28 82±22 83±19 81±20 83±18 0.08
Kidney function
Serum creatinine (mg per 100ml) 0.9 (0.8–1.1) 0.9 (0.7–1.0) 1.0 (0.7–1.2) 1.2 (1.0–1.8) 1.3 (0.9–1.6) o0.0001
Estimated GFR (ml/min)a 86±19 84±20 76±25 57±23 61±25 o0.0001
Medical therapy
Aspirin 1627 (98) 61 (100) 92 (97) 58 (97) 79 (94) 0.10
Beta-blockers 1466 (82) 52 (85) 83 (87) 49 (82) 61 (78) 0.06
ACE inhibitor/ARB 1401 (84) 49 (80) 81 (85) 49 (82) 58 (74) 0.18
Reperfusion therapy
Any reperfusion therapy 1062 (64) 38 (62) 48 (51) 30 (50) 32 (41) o0.0001
Thrombolytic therapy 472 (28) 8 (13) 17 (18) 9 (15) 17 (22) 0.002
Primary angioplasty 590 (36) 30 (49) 31 (33) 21 (35) 15 (19) 0.006
Contrast volume (ml) 193±60 198±48 209±62 198±48 200±53 0.63
ACE, angiotensin-converting enzyme; AKI, acute kidney injury; ARB, angiotensin II receptor blockers; GFR, glomerular filtration rate; SBP, systolic blood pressure.
Data are number (%), mean±s.d., or median (interquartile range).
aOn the basis of abbreviated MDRD (Modification of Diet in Renal Disease) study equation.38
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markedly attenuated by adjustments for baseline eGFR and
other clinical variables but remained statistically significant.
The adjusted long-term mortality risk of patients with
transient mild AKI was comparable with that of patients
without AKI. However, persistent mild AKI was associated
with an adjusted hazard ratio of 1.8 compared with patients
without AKI. Patients with persistent moderate/severe AKI
had the highest mortality, whereas those with transient
moderate/severe AKI had an intermediate risk, close to that
of patients with persistent mild AKI (Table 2).
There was a significant interaction between baseline eGFR
and AKI groups with regard to the primary end point of all-
cause mortality. The hazard ratios for mortality for the AKI
categories were higher among patients with higher baseline
eGFR. For example, in patients with persistent moderate/
severe AKI, the adjusted hazard ratio for mortality was 6.6
(95% CI: 3.5–12.1, Po0.0001) in patients with baseline eGFR
X60 ml/min and 1.7 (95% CI: 1.1–3.0, P¼ 0.03) in patients
with baseline eGFR o60 ml/min.
Similar results were obtained when AKI was defined using
eGFR cutoffs. Compared with patients without AKI, the
adjusted hazard ratios were 1.0 in transient mild AKI (95%
CI: 0.5–2.0, P¼ 0.99), 2.3 in persistent mild AKI (95% CI:
1.4–3.7, P¼ 0.001), 2.0 in transient moderate/severe AKI
(95% CI: 1.2–3.2, P¼ 0.004), and 2.7 in persistent moderate/
severe AKI (95% CI: 1.5–4.6, P¼ 0.001).
AKI, admissions for heart failure, and recurrent infarctions
The relationships between AKI and the secondary end
points of admission for the treatment of heart failure (HF)
and recurrent infarction are shown in Table 3. The relation-
ship between the presence and severity of AKI and read-
missions for the treatment of HF had a similar pattern to
that of mortality. By contrast, the incidence of recurrent
infarction was not significantly different across categories
of AKI.
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Figure 1 | Box-and-whisker plots of changes in creatinine
levels during hospitalization in patients with (a) mild and (b)
moderate/severe acute kidney injury (AKI). In each AKI group,
baseline and peak creatinine levels were similar in patients with
transient and persistent AKI. The line within the box denotes the
median and the box spans the interquartile range (25th–75th
percentiles). Whiskers extend from 1.5 times the interquartile
range lower than the first quartile to 1.5 times the interquartile
range higher than the third quartile. *Mann–Whitney Po0.0001
for the comparison of pre-discharge creatinine level of patients
with transient vs persistent AKI.
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Figure 2 |Kaplan–Meier survival curves according to acute kidney injury (AKI) categories (comparison by log-rank test).
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DISCUSSION
This study shows that dynamic changes in renal function
during hospitalization for AMI are associated with changes in
long-term outcome. After the initial AKI, improvement in
renal function within the index hospitalization was observed
in 39.1% of patients with mild AKI and 43.5% of patients
with moderate/severe AKI. There was a graded independent
association between severity of AKI during the acute phase of
the infarction and mortality after discharge. Importantly,
regardless of the severity of the initial AKI, improvement in
renal function was associated with lower long-term mortality.
In addition, the outcome of patients with transient mild AKI
was similar to that of patients who maintained their baseline
renal function throughout the hospitalization.
AKI is a common event in the acute phase of myocardial
infarction. Depending on the definition used, its frequency
ranges between 9.6 and 19.4%.3,4,6 It is a complex multi-
factorial phenomenon preconditioned by underlying renal
dysfunction and modulated by multiple contributing factors.
These include hemodynamic alterations, changes in volume
status, neurohormonal activation, medical therapies such as
diuretics and agents that affect the renin–angiotensin–aldos-
terone axis and the use of contrast media.15 Although many
of these factors may affect renal function in a reversible
manner, there is no information regarding the incidence and
clinical significance of transient vs persistent AKI in patients
with STEMI. This study adds to the existing information by
exploring the relationship between transient vs persistence of
AKI and outcome. In keeping with earlier studies,3,16 we
found a graded relationship between severity of AKI and
long-term mortality. However, for each level of AKI, the
outcome of patients with persistent AKI was worse than that
of those with transient AKI.
There is accumulating evidence that small increments in
serum creatinine are associated, in various settings, with
adverse outcomes.3,4,6,17,18 On the basis of Acute Kidney
Table 2 | Unadjusted and adjusted Cox proportional hazards model for mortality after hospital discharge according to changes
in creatinine levels during hospitalization and baseline eGFRa
n Events (%) Unadjusted HR (95% CI) P-value Adjusted HR (95% CI) P-value
AKI
None 1633 143 (8.6) 1.0 (Referent) 1.0 (Referent)
Transient mild AKI 61 9 (14.8) 1.7 (0.8–3.2) 0.14 1.2 (0.6–2.3) 0.64
Persistent mild AKI 95 18 (18.9) 2.5 (1.5–4) o0.0001 1.8 (1.1–3.0) 0.020
Transient moderate/severe AKI 60 22 (36.7) 4.5 (2.8–7.0) o0.0001 1.7 (1.1–2.8) 0.026
Persistent moderate/severe AKI 78 35 (44.9) 6.5 (4.5–9.3) o0.0001 2.4 (1.6–3.7) o0.0001
Baseline eGFR (ml/min per m2)b
X90ml/min 782 42 (5.4) 1.0 (Referent) 1.0 (Referent)
60–89ml/min 837 79 (9.4) 1.8 (1.3–2.7) 0.001 1.3 (0.9–1.9) 0.0.16
30–59ml/min 304 83 (27.3) 6.6 (4.5–9.5) o0.0001 2.4 (1.6–3.7) o0.0001
o30ml/min 34 17 (55) 12.6 (7.1–22.1) o0.0001 2.4 (1.2–4.6) 0.009
AKI, acute kidney injury; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
aThe final model adjusted for age, gender, estimated glomerular filtration rate, previous diuretic therapy, history of hypertension, diabetes, smoking, previous myocardial
infarction, presence of anterior infarction, Killip class, heart rate and blood pressure on admission, use of reperfusion therapy (thrombolytic therapy or primary angioplasty),
medical therapy (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and beta-blockers), and left ventricular ejection fraction.
beGFR was calculated using the abbreviated MDRD (Modification of Diet in Renal Disease) study equation.38
Table 3 | Association between changes in creatinine levels during hospitalization and secondary end pointsa
n Events (%) Unadjusted HR (95% CI) P-value Adjusted HR (95% CI) P-value
Admission for heart failure
No AKI 1633 148 (9.1) 1.0 (Referent) 1.0 (Referent)
Transient mild AKI 61 11 (18.0) 2.2 (1.7–4.1) 0.01 1.5 (0.8–2.8) 0.18
Persistent mild AKI 95 19 (20.0) 2.7 (1.7–4.3) o0.0001 1.7 (1.1–2.8) 0.03
Transient moderate/severe AKI 60 18 (30.0) 4.7 (2.9–7.6) o0.0001 1.7 (1.1–2.9) 0.04
Persistent moderate/severe AKI 78 18 (23.1) 3.9 (2.4–6.3) o0.0001 2.0 (1.2–3.3) 0.008
Recurrent infarction
No AKI 1633 180 (11.0) 1.0 (Referent) 1.0 (Referent)
Transient mild AKI 61 4 (6.6) 0.7 (0.3–1.8) 0.45 0.6 (0.2–1.8) 0.39
Persistent mild AKI 95 15 (15.8) 1.6 (0.9–2.8) 0.10 1.6 (0.9–1.8) 0.12
Transient moderate/severe AKI 60 9 (15.0) 1.7 (0.8–3.5) 0.14 1.4 (0.7–3.0) 0.34
Persistent moderate/severe AKI 78 9 (11.5) 1.5 (0.8–3.0) 0.20 1.4 (0.7–2.8) 0.36
AKI, acute kidney injury; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
aThe final models were adjusted for age, gender, estimated glomerular filtration rate (MDRD), previous diuretic therapy, history of hypertension, diabetes, smoking, previous
myocardial infarction, presence of anterior infarction, Killip class, heart rate and blood pressure on admission, use of reperfusion therapy (thrombolytic therapy or primary
angioplasty), medical therapy (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and beta-blockers), and left ventricular ejection fraction.
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Injury Network recommendations, stage 1 AKI is defined as
an abrupt (o48-h) increase in serum creatinine level of
X0.3 mg per 100 ml above baseline.19 Previous studies
suggest even such mild increase in serum creatinine is
associated with increased long-term risks in the setting of
decompensated HF18,20 and AMI.3,6,16 However, our results
indicate that in cases where this mild AKI is transient, long-
term mortality is not affected. In such cases, mild transient
AKI may represent a reversible renal impairment secondary
to nephrotoxic agents, hemodynamic alterations, or changes
in volume status. A substantial improvement in long-term
outcome was also observed in patients with transient
moderate/severe AKI. Interestingly however, when AKI was
moderate or severe, subsequent improvement in renal
function was associated with only a partial improvement in
outcome, with a substantial increase in mortality and HF
compared with patients who had stable renal function.
Therefore, AKI, even if transient, may serve as a simple
biomarker of adverse physiological events that portend worse
outcomes such as increased neuro-hormonal activation
during the acute phase of AMI.
Chronic kidney disease is a well-described predictor of
adverse outcome in patients with AMI.4,10,11,21,22 However,
several recent studies have shown that the occurrence of AKI
in the setting of AMI provides incremental prognostic
information over baseline renal function.3,4,6,23 The under-
lying mechanisms for the association between small changes
in serum creatinine level and adverse outcomes in patients
with AMI are poorly understood. Small decreases in renal
function during hospitalization may be associated with renal
function loss after hospital discharge.24 In addition, an
episode of transient AKI may leave a permanent subclinical
renal damage that may lead to progressive deterioration
of renal function and development of chronic kidney
disease.16,25–27
Increased risk of accelerated atherosclerosis may occur
with minor renal dysfunction, and expose the patient with a
cardiac event to an excessive cardiac mortality.28,29 The
increased risk of long-term mortality in patients with AKI,
therefore, may be associated with these primary effects of
decreases in kidney function.
However, previous studies examined the association
between AKI and the end point of all-cause mortality.
Our data provide further insight by showing a graded
association between the magnitude of AKI and subsequent
hospitalizations for the treatment of HF rather than
recurrent infarctions. These results suggest AKI in the
setting of AMI represents, in part, subclinical or overt HF.
The profound hemodynamic and neuro-hormonal altera-
tions that are associated with a rapid worsening of cardiac
function in AMI30–34 may lead to a decline in renal
function3,4,6,35 and the development of the type I cardiorenal
syndrome.36
The results of this study clearly show that the documenta-
tions of AKI at one time point provide only partial
prognostic information in patients with AMI. Our study
also shows that although even transient AKI in patients with
AMI portends increased long-term mortality, patients with
persistent AKI are in the highest risk group.
Study limitations
Our study has several limitations. Because of methodo-
logical limitations inherent in retrospective analyses, our
data cannot definitely establish an etiological link between
transient or persistent AKI after ST-elevation infarction
and the observed increased risk of death. In addition, our
data cannot address whether prevention of such seemingly
modest increases in creatinine levels can influence outcome
after AMI.
Information regarding creatinine levels was limited to
hospital discharge information. It is possible that in some
patients, improvement in renal function begins or continues
after hospital discharge. Serum creatinine measurements
were not carried out routinely in all patients after 72 h post
admission. Therefore, some of the patients with AKI could be
misclassified as not having AKI, or in cases of early AKI as
persistent rather than transient AKI. This could lead to
underestimation of the effect of AKI on mortality. especially
in case of transient AKI. Finally, we did not address the
influence of different therapies that were administered during
the acute phase of the infarction on the changes in renal
function.
Conclusion
Dynamic changes in renal function during the acute phase of
STEMI are strongly related to long-term mortality and HF
after hospital discharge. Improvements in renal function after
AKI are common and portend better outcomes.
MATERIALS AND METHODS
Patients
We used a prospective database consisting of all patients admitted to
the cardiac intensive care unit of the Rambam Medical Center
(Haifa, Israel), with the diagnosis of acute STEMI. We used the Joint
European Society of Cardiology/American College of Cardiology
criteria37 as follows: (1) ischemic symptoms lasting for at least
20 min; (2) new or presumed new ST segment elevation at the J
point in two or more contiguous leads with the cutoff points
X0.2 mV in leads V1, V2, or V3 and X0.1 mV in other leads; and
(3) typical increase in biochemical markers of myocardial necrosis.37
We excluded patients who died during hospital stay in an
attempt to avoid several potential biases as follows: (1) Some
patients die very early after admission without any repeated
creatinine measurements. (2) Survival bias may occur such that
some patients with one or two repeated creatinine measurements
did not survive long enough and serum creatinine may not have
sufficient time to increase despite significant renal injury. (3) Even in
patients with increasing creatinine, early in-hospital death precludes
correct classification of AKI severity.
Qualifying patients received reperfusion therapy with primary
angioplasty of thrombolytic agents according to the discretion of the
attending cardiologist. In most patients, assessment of the left
ventricular ejection fraction by echocardiography was carried out on
days 2–3 of hospitalization or earlier if clinically indicated. The
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investigational review committee on human research approved the
study protocol.
Assessment of renal function
Venous blood samples were obtained on admission and at 24, 48,
and 72 h thereafter. After the first 72 h from admission, creatinine
measurements were determined only when clinically indicated.
eGFR was calculated on the basis of the abbreviated MDRD
(Modification of Diet in Renal Disease) study equation, which is
currently recommended as a prediction equation for estimation of
GFR in clinical practice.38,39
Definitions of AKI
The cutoffs for AKI were chosen based on changes in calculated
eGFR and absolute changes in creatinine levels during hospitaliza-
tion. These cutoffs were based on the proposed criteria of the Acute
Kidney Injury Network19 and the RIFLE classification system,40 and
on evidence from previous studies that these cutoffs are associated
with increased mortality in patients with AMI.2–4
For cutoffs based on absolute creatinine differences, mild AKI
was defined as peak creatinineX0.3–0.49 mg per 100 ml higher than
admission creatinine, and moderate/severe AKI as an increase in
serum creatinine X0.5 mg per 100 ml compared with admission
value at any point during the hospitalization. Using eGFR cutoffs,
mild AKI defined as a X25–49% decrease in eGFR and moderate/
severe AKI as X50% decrease in eGFR.
The study patients were divided into five groups based on
creatinine changes during hospital course as follows: (1) patients
without AKI; (2) patients with mild AKI that resolved by discharge
(transient mild AKI) (In this group, peak creatinine during hospital
course was X0.3–0.49 mg per 100 ml higher than admission
creatinine, but pre-discharge creatinine returned to a level that
was o0.3 mg per 100 ml higher than admission creatinine.); (3)
patients with mild AKI that did not resolve by discharge (persistent
mild AKI); (4) patients with moderate/severe AKI that resolved by
discharge (transient moderate/severe AKI) (In these patients, peak
creatinine during hospital course was X0.5 mg per 100 ml higher
than admission creatinine, but pre-discharge creatinine returned to
a level that was o0.5 mg per 100 ml higher than admission
creatinine); and (5) patients with moderate/severe AKI that did
not resolve by discharge (persistent moderate/severe AKI).
Similarly, the study participants were divided into five groups
based on eGFR changes as follows: (1) patients without AKI;
(2) transient mild AKI (In these patients, nadir eGFR during
hospital course wasX25–49% lower than admission eGFR, but pre-
discharge eGFR returned to a level that was o25% lower than
admission eGFR); (3) persistent mild AKI; (4) transient moderate/
severe AKI (In these patients, nadir eGFR during hospital course was
X50% lower than admission eGFR, but pre-discharge creatinine
returned to a level that waso50% lower than admission eGFR); and
(5) persistent moderate/severe AKI.
Study end point
The primary end point of the study was all-cause mortality after
hospital discharge.41 Secondary end points included readmission for
the management of HF (defined by the presence of new symptoms
of dyspnoea with pulmonary venous congestion on X-ray with
interstitial or alveolar edema) and recurrent infarctions. After
hospital discharge, clinical end point information was acquired
through the national death registry and by contacting each patient
individually and independently reviewing hospital charts for major
clinical events if the patient had been re-hospitalized.
Statistical analysis
Data are expressed as mean±s.d. or median and interquartile range.
The baseline characteristics of the groups were compared using
analysis of variance (ANOVA) for continuous variables and by the
w2 statistic for noncontinuous variables. When continuous data were
not normally distributed or had unequal variance, groups were
compared with the nonparametric one-way ANOVA (Kruskal–Wallis
test). Comparisons between creatinine levels at various time points
were carried out using the Mann–Whitney U-test.
The multivariable logistic regression model with backward
stepwise selection was carried out to identify independent predictors
of AKI during hospitalization. Predictors of mild AKI and
moderate/severe AKI were similar. Therefore, we provide one model
for predictors of any creatinine elevation X0.3 mg per 100 ml.
Event-free survival was estimated using the Kaplan–Meier
method, and curves were compared with the log-rank test. The
univariate and multivariate Cox proportional hazard analyses were
carried out to determine the relation between AKI categories and
mortality, with patients without AKI as the reference group. After
forcing AKI categories and baseline eGFR into each model, the
backward stepwise variable selection was used to generate the final
model. The following baseline clinical characteristics were con-
sidered in the multivariate procedure: age, gender, history of
previous infarction, history of diabetes, history of hypertension,
smoking status, baseline eGFR, Killip class II–IV on admission,
hypotension (systolic blood pressureo100 mm Hg) and tachycardia
(heart rate 4100 beats/min) on admission, anterior location of
infarction, thrombolytic therapy and primary angioplasty.42 The
model also adjusted for left ventricular ejection fraction using a
dummy variable for coding missing left ventricular ejection fraction
(n¼ 172; 8.8%).
Separate models were designed for the secondary end points. The
proportional hazard assumption was evaluated and satisfied for
these multivariable survival analyses by examining plots of
Schoenfeld residuals for each covariate. Differences were considered
statistically significant at the two-sided Po0.05 level. All
statistical analyses were carried out using the SPSS (Chicago, IL,
USA) statistical software (version 15.0).
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